SCHEMBL32685347

SCHEMBL32685347

C[C@@H]1CN(c2cccnn2)CCN1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PRKCQ Q04759 3/20 0.49
PRKCD Q05655 1/20 0.49
CSNK1E P49674 2/20 0.42
PIM1 P11309 1/20 0.40
PIM3 Q86V86 1/20 0.40
PIM2 Q9P1W9 1/20 0.40
HDAC1 Q13547 1/20 0.40
ACVR1 Q04771 1/20 0.40
KHK P50053 1/20 0.39
TRPV1 Q8NER1 1/20 0.39
KIT P10721 1/20 0.38
MAPK13 O15264 1/20 0.38
MAPK12 P53778 1/20 0.38
MAPK11 Q15759 1/20 0.38
MAPK14 Q16539 1/20 0.38
CDK4 P11802 2/20 0.37
CDK6 Q00534 2/20 0.37
SLC6A7 Q99884 1/20 0.37
BCL2A1 Q16548 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32685342 1.00 PRKCQ (0.49) PRKCQPRKCDCSNK1EPIM1PIM3
SCHEMBL32685344 1.00 PRKCQ (0.49) PRKCQPRKCDCSNK1EPIM1PIM3
SCHEMBL30146604 0.85 PRKCQ (0.40) PRKCQPRKCDCSNK1EHDAC1ACVR1
SCHEMBL4779990 0.82 PRKCQ (0.53) PRKCQPRKCDHDAC1TRPV1
SCHEMBL32685345 0.82 PRKCQ (0.53) PRKCQPRKCDHDAC1TRPV1
SCHEMBL32685368 0.82 PRKCQ (0.53) PRKCQPRKCDHDAC1TRPV1
SCHEMBL31745447 0.79 PLD1 (0.60) PRKCQPRKCDCSNK1EHDAC1ACVR1
SCHEMBL2244221 0.79 PLD1 (0.60) PRKCQPRKCDCSNK1EHDAC1ACVR1
SCHEMBL234735 0.79 PLD1 (0.60) PRKCQPRKCDCSNK1EHDAC1ACVR1
SCHEMBL709716 0.79 PLD1 (0.60) PRKCQPRKCDCSNK1EHDAC1ACVR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577226-B2 Compounds for treating Huntington's disease PTC THERAPEUTICS, INC. (US) 2026-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577226-B2 Compounds for treating Huntington's disease HTT, HYPK, GRIN2C PRKCQ 3806/4885PRKCD 3328/4885CSNK1E 1400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.